Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies

2011317 citationsJournal Articlehybrid Open Access

Authors

Mohamed L. Sorror · Fred Hutch Cancer Center

Brenda M. Sandmaier · University of Washington

Barry E. Storer · University of Washington

Georg‐Nikolaus Franke · University Hospital Leipzig

Ginna G. Laport · Stanford Blood Center

Thomas R. Chauncey · University of Washington

Edward Agura

Abstract

Among patients aged 60 to 75 years treated with nonmyeloablative allogeneic HCT, 5-year overall and progression-free survivals were 35% and 32%, respectively.

Topics & Keywords

Hematopoietic Stem Cell Transplantation Childhood Cancer Survivors' Quality of Life Immune Cell Function and Interaction

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA

Volume 306, Issue 17, pp. 1874-1874

DOI: 10.1001/jama.2011.1558

Field-Weighted Citation Impact: 12.00